Xeomin Purple Book BLA 125360

BLA number
125360
Proprietary names
Xeomin
Proper names
incobotulinumtoxinA
Applicant
Merz Pharmaceuticals GmbH c/o Merz Pharmaceuticals LLC
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001XeominincobotulinumtoxinA351(a)50UNITSFor InjectionIntramuscular, IntraglandularSingle-Dose VialRxLicensed2010-07-30
002XeominincobotulinumtoxinA351(a)100UNITSFor InjectionIntramuscular, IntraglandularSingle-Dose VialRxLicensed2010-07-30
003XeominincobotulinumtoxinA351(a)200UNITSFor InjectionIntramuscular, IntraglandularSingle-Dose VialRxLicensed2015-11-20

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-05-01U001Xeomin351(a)RxMerz Pharmaceuticals GmbH c/o Merz Pharmaceuticals LLC
2021-05-01U002Xeomin351(a)RxMerz Pharmaceuticals GmbH c/o Merz Pharmaceuticals LLC
2021-05-01U003Xeomin351(a)RxMerz Pharmaceuticals GmbH c/o Merz Pharmaceuticals LLC
2020-05-01R001Xeomin351(a)RxMerz Pharmaceuticals GmbH
2020-05-01R002Xeomin351(a)RxMerz Pharmaceuticals GmbH
2020-05-01R003Xeomin351(a)RxMerz Pharmaceuticals GmbH

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Xeomin351(a)RxLicensed2010-07-30
2020-05-01002Xeomin351(a)RxLicensed2010-07-30
2020-05-01003Xeomin351(a)RxLicensed2015-11-20